Status: Not yet recruiting
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
Participants needed: 96
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Philogen S.p.A.Updated: May 5, 2026Locations: 1
Eligibility criteria
at least one prior line containing FOLFIRINOX and/or gemcitabine plus nab-paclit... [+20]
Patients with primary brain tumors, brain metastases or CNS disease will be excl... [+19]